Pharscin Pharma(SZ:002907) Sou Hu Cai Jing·2025-08-13 13:04Core Insights - The stock price of Huason Pharmaceutical (002907) closed at 18.01 yuan on August 13, 2025, with a slight increase of 0.06% [1] - The company reported a total revenue of 239 million yuan for Q1 2025, reflecting a year-on-year growth of 4.62% [1] - The net profit attributable to shareholders was approximately 40.36 million yuan, showing a marginal increase of 0.01% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 239 million yuan, up 4.62% year-on-year [1] - Net profit attributable to shareholders: 40.36 million yuan, up 0.01% year-on-year [1] - Non-recurring net profit: 37.67 million yuan, up 1.08% year-on-year [1] - Current ratio: 5.198, Quick ratio: 4.589, Debt-to-asset ratio: 12.95% [1] Market Activity - The trading volume was 120,400 lots, with a transaction amount of 216 million yuan [1] - Main funds experienced a net outflow of approximately 16.80 million yuan, accounting for 7.78% of the transaction amount [1] - Small orders saw a net inflow of approximately 21.41 million yuan, representing 9.92% of the transaction amount [1] Company Background - Huason Pharmaceutical was established in 1996 and is located in Chongqing, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of approximately 4.18 billion yuan and a paid-in capital of 777 million yuan [1][2] - The legal representative of the company is You Hongtao [1] Investment and Intellectual Property - The company has made investments in 12 enterprises and participated in 4,250 bidding projects [2] - It holds 204 trademark registrations and 135 patents, along with 210 administrative licenses [2]